Cancer
Proton Pump Inhibitors Linked to Poor Survival Outcomes in Gastric Cancer Patients
A study published in the British Journal of Clinical Pharmacology has found that proton pump inhibitors (PPIs) are associated with shorter progression-free survival in patients with advanced gastric cancer receiving ramucirumab, a vascular endothelial growth factor receptor 2 (VEGFR2)-targeting monoclonal antibody, plus paclitaxel or nab-paclitaxel. Researchers from the University